surface facing the internal aqueous phase of the liposome 5 8 . Therefore, when preparing liposomes using PEG lipids, or modifying ligands to PEG on the liposome surface, more PEG lipids or ligands are required compared with the original design to obtain the expected effect. This problem becomes more serious when expensive materials are used, and the increased cost makes it difficult to develop and commercialize drugs for cancer treatment 8 . In addition, it was reported that hydrolysis of PEG lipids was promoted when pH-gradient method was used to encapsulate drug in liposomes 5, 6 . In this method, to effectively dissolve and encapsulate the drug in the internal aqueous phase of liposomes, the internal aqueous phase is adjusted to pH conditions at which the drug becomes water-soluble, and a pH gradient is generated between the outer aqueous phase and the inner aqueous phase. Recently, a method of adding PEG after liposome formation post-insertion was studied. In this method, since PEG is modified only on the mem-brane surface facing the outer aqueous phase of the liposomes, the amount of PEG lipid or ligands required is smaller than that of pre-insertion, and by modifying PEG under physiological pH conditions, it is possible to suppress its decomposition 5 8 .
PEGylation is particularly important in treating cancer using boron neutron capture therapy BNCT . BNCT is a cancer therapy using nuclear reactions between boron-10 10B and thermal neutrons. Since the high linear energy transfer particles have limited path lengths in tissue 5-9 µm , the destructive effects of high-energy 2.3 MeV particles generated in BNCT α particles and recoiling lithium-7 nuclei are limited to boron-containing cells. For BNCT to be successful, it is essential that 10B atoms are selectively delivered and accumulated in the interstitial space of tumor tissue and/or the intracellular space of tumor cells 9, 10 . Studies on the PEGylation of formulations or the modification of ligands to PEG chains on the formulation surface to efficiently deliver the drug to tumor cells have been reported 11 13 . However, little has been reported on the influences of pre-insertion and post-insertion in boron delivery.
The main aim of the present study was to investigate the utility of polyborane-encapsulated PEGylated liposomes prepared using post-insertion technique post-PEG liposomes in boron delivery for BNCT. 2-Dicarba-closo-dodecaborane succinic acid Fig. 1 synthesized from 1,2-dicarba-closo-dodecaborane was used as a boron carrier 14 . The liposomes were compared with non-PEGylated polyboraneencapsulated liposomes bare liposomes and PEGylated polyborane-encapsulated liposomes prepared with pre-insertion technique pre-PEG liposomes . In vitro toxicity and cellular uptake tests were performed on polyboraneencapsulated liposomes. The effectiveness in cancer treatment using BNCT was assessed by biodistribution study in tumor-bearing mice. 
Preparation of polyborane-encapsulated liposomes
2-Dicarba-closo-dodecaborane succinic acid encapsulated liposomes bare liposomes were prepared using the Bangham method and the remote loading 15 17 . Lipid mixtures of lecithin from egg yolk 0.60 mmol and cholesterol 0.40 mmol were dissolved in 10 mL of chloroform in an eggplant flask, and chloroform was evaporated under reduced pressure. After a thin film was formed in the eggplant flask, it was further dried under reduced pressure for 24 h. The thin film was hydrated with Glycine-NaOH buffer pH 10.6 to obtain a liposome suspension. Liposomes with a mean volume diameter of 100 nm were prepared using a Lipex Extruder Northern Lipid Inc., Burnaby, Canada and polycarbonate membranes Nuclepore Track-Etched Membranes, Whatman Inc., Florham Park, NJ . To obtain liposomes of desired size, the sample was passed through three types of polycarbonate membranes pore sizes: 800, 200, and 100 nm five times each 14 . The mixtures of 2 mL of the prepared liposome suspension and 2 mL of HEPES buffered saline pH 7.4 were centrifuged at 60,000 rpm for 30 min at 4
Himac 80WX, Hitachi Koki Co. Ltd., Tokyo, Japan . After removal of the supernatant fluid, the precipitated liposomes were redispersed in 2 mL of HEPES buffered saline pH 7.4 . 2-Dicarba-closo-dodecaborane succinic acid 0.25 mmol was added to the suspension, and it was encapsulated in liposomes by incubation at 65 for 30 min. To remove residual 2-dicarba-closo-dodecaborane succinic acid, the sample was centrifuged at 60,000 rpm for 30 min at 4 . After removal of the supernatant fluid, the precipitated liposomes were redispersed in 2 mL of HEPES buffered saline pH 7.4 , and polyborane-encapsulated liposomes with a mean volume diameter of 100 nm bare li- Fig. 1 2-Dicarba-closo-dodecaborane succinic acid. posomes were obtained.
Preparation of polyborane-encapsulated PEGylated liposomes
We prepared two types of polyborane-encapsulated PE-Gylated liposomes using pre-insertion and post-insertion 5, 6 . In pre-insertion method, lipid mixtures of lecithin from egg yolk 0.50 mmol , cholesterol 0.40 mmol , and DSPE-PEG 0.10 mmol were dissolved in 10 mL of chloroform in an eggplant flask, and polyborane-encapsulated PEGylated liposomes pre-PEG liposomes were prepared in the same manner as described in section 2.2. In post-insertion method, lipid mixtures of lecithin from egg yolk 0.55 mmol and cholesterol 0.40 mmol were dissolved in 10 mL of chloroform in an eggplant flask, and chloroform was evaporated under reduced pressure. After a thin film was formed in the eggplant flask, it was further dried under reduced pressure for 24 h. The thin film was hydrated with Glycine-NaOH buffer pH 10.6 to obtain a liposome suspension. Liposomes with a mean volume diameter of 100 nm were prepared using a Lipex Extruder and polycarbonate membranes. To obtain liposomes of desired size, the sample was passed through three types of polycarbonate membranes pore sizes: 800, 200, and 100 nm five times each 14 . The mixtures of 2 mL of the prepared liposome suspension and 2 mL of HEPES buffered saline pH 7.4 were centrifuged at 60,000 rpm for 30 min at 4 Himac 80WX . After removal of the supernatant fluid, the precipitated liposomes were redispersed in 2 mL of HEPES buffered saline pH 7.4 . DSPE-PEG 0.05 mmol was added to the suspension, and the sample was incubated at 65 for 1 h to obtain PEGylated liposomes. Then, 2-dicarba-closododecaborane succinic acid 0.25 mmol was added to the PEGylated liposome suspension, and it was encapsulated in liposomes by incubation at 65 for 30 min. To remove residual 2-dicarba-closo-dodecaborane succinic acid, the samples were centrifuged at 60,000 rpm for 30 min at 4 . After removal of the supernatant fluid, the precipitated liposomes were redispersed in 2 mL of HEPES buffered saline pH 7.4 , and polyborane-encapsulated PEGylated liposomes with a mean volume diameter of 100 nm post-PEG liposomes were obtained.
Physicochemical properties of polyborane-encapsulated bare and PEGylated liposomes
The mean volume diameter and the size distribution of the prepared liposomes were determined using a dynamic light scattering system ELSZ-1000ZS, Otsuka Electronics Co., Ltd., Hirakata, Japan , which measures the scattered light that is generated when laser light is irradiated onto particles that are in Brownian motion, at 25 . Also, zeta potentials of liposomes were measured in HEPES buffered saline pH 7.4 with an ionic strength of 0.154 M at 37 . The data were analyzed by using Ohshima s electrokinetic theory for a spherical colloidal particle 18 , and the surface charge density σ was obtained using the following formula.
where e is the elementary electric charge, ε r is the relative permittivity of the solution, ε 0 is the permittivity of a vacuum, k is the Boltzmann constant, and T is the absolute temperature. The ionic strength I was given by where ζ is the zeta potential, κ is the Debye-Hiickel parameter, and a is the particle radius. The fixed aqueous layer thickness FALT on the liposomal membrane, which is an important factor to avoid capture by reticuloendothelial system, was also calculated from the zeta potential values 19 . Zeta potentials of liposomes used for the calculation were measured in HEPES buffered saline pH 7.4 with nine different ionic strengths I 0.005 M, 0.010 M, 0.020 M, 0.040 M, 0.060 M, 0.075 M, 0.100 M, 0.125 M, and 0.154 M at 37 . Boron concentrations of the liposomes were determined using inductively coupled plasma atomic emission spectroscopy ICP-AES, ICPE-9000, Shimadzu Corp., Kyoto, Japan . A calibration curve was prepared using boron standard solution. The boron concentration was calculated from the peak intensity observed at a wavelength of 249.773 nm using the calibration curve. All ICP-AES measurements were carried out under the same conditions. Morphological observation of the liposomes was carried out using transmission electron microscope TEM, H-7650, Hitachi High-Technologies Co., Ltd., Tokyo, Japan . Samples were negatively stained using a 0.2 w/v of phosphotungstic acid solution, and they were stored in a desiccator for 24 h to completely remove the solvent 20 .
In vitro release study of polyborane from liposomes
To evaluate the influence of PEGylation methods on drug release behavior, the release rate of polyborane from the liposomes were studied. Liposome suspensions were diluted with phosphate-buffered saline PBS to a concentration of 0.25 mg/mL and shaken at 100 rpm at 37 . After 0.5, 1, 2, 4, 8, 12, and 24 h, the samples were taken and centrifuged at 60,000 rpm for 30 min at 4 . Then, the boron concentration in the supernatant was measured using ICP-AES, and the release rate of polyborane was calculated.
In vitro cytotoxicity tests of liposomes
Cytotoxicity tests were performed using the WST-8 assay 21 . Cell Count Reagent SF Nacalai Tesque Inc. was used as a reagent, and the assay was performed according to the manufacturer s instructions. B16 melanoma or RAW264.7 cells, which were cultured in DMEM containing 10 FBS, were used. Briefly, 100 µL of the cell suspension was seeded in a 96-well plate at 5.0 103 cells/well. After culturing for 24 h at 37 in a 5 CO 2 atmosphere, 10 µL of a polyborane solution or liposomal suspensions were added and further cultured for 24 h at 37 in a 5 CO 2 atmosphere. The boron concentration of all samples was adjusted to 40 mg/L. Ten microliters of the reagent was added and color reaction was carried out for 1 h. Then, absorbance of each well was measured using a microplate reader ARVO X4, PerkinElmer Inc., Waltham, MA at 450 nm to calculate cell viability.
In vitro cell uptake tests of liposomes
One milliliters of the suspension of B16 melanoma or RAW264.7 cells was seeded in a 24-well plate at 2.0 105 cells/well and cultured for 24 h at 37 in a 5 CO 2 atmosphere 22 . After washing three times with PBS, 1.0 mL of the polyborane solution or liposomal suspensions were added and further cultured for 24 h at 37 in a 5 CO 2 atmosphere. The boron concentration of all samples was diluted to 40 mg/L using DMEM containing 10 FBS. Then, the boron concentration in the supernatant was measured using ICP-AES.
Biodistribution study of polyborane-encapsulated li-
posomes in tumor-bearing mice Mice ddY, 4 weeks old, male were housed in stainless steel cages and housed under standard environmental conditions 23 1 , 55 5 humidity and a 12/12 h light/dark cycle and maintained with free access to water and a standard laboratory diet carbohydrates 30 ; proteins 22 ; lipids 12 ; vitamins 3 ad libitum Nihon Nosan Kogyo Co., Yokohama, Japan . The experiment was conducted in accordance with the Guidelines for Animal Experimentation of Tokyo University of Science, which are based on the Guidelines for Animal Experimentation of the Japanese Association for Laboratory Animal Science. B16 melanoma cells 1.0 106 cells in 50 µL of PBS were subcutaneously injected into a footpad of the right hind limb of mice, and tumor-bearing mice were given after 2-3 weeks 14, 23, 24 . The experiment started when the estimated tumor weight reached 80-100 mg. Estimates of tumor weight in mg were calculated using the following formula.
Tumor weight
L W 2 2 where L is the length mm and W is the width mm 25 . The polyborane solution or liposome suspensions 10.0 mg boron/kg, in PBS were injected into tumor-bearing mice via the tail vein with isoflurane anesthesia, and animals were maintained in metabolic cages. The injections were well tolerated and no adverse effects were observed. After 24 h of sample administration, mice were euthanized via cervical dislocation under anesthesia and bled at inferior vena cava. The tumor, brain, heart, lungs, liver, stomach, pancreas, spleen, and kidneys were immediately taken from the same individual. The blood, urine, feces, and all tissues were weighed and melted using wet ashing method with nitric acid 26 . All boron amounts of samples were determined using ICP-AES.
Results and Discussion
3.1 Characterization of polyborane-encapsulated liposomes 2-Dicarba-closo-dodecaborane succinic acid encapsulated bare, pre-PEG, and post-PEG liposomes with average sizes of approximately 100 nm were prepared. The mean volume diameters, the polydispersity indexes, and the values of encapsulation efficacy of polyborane are summarized in Table 1 . Liposomes had a similar polydispersity indexes. The encapsulation efficacies of liposomes were raised by preparing the liposomes using pH gradient, which is one of the methods to actively contain polyborane in liposomes 27 . The particle size distributions and TEM images of liposomes were shown in Figs. 2 and 3 , respectively, and we confirmed that bare, pre-PEG, and post-PEG liposomes were spherical dispersed particles. Their electrophoretic mobility was also measured, and the surface charge density was obtained Fig. 4 18 . The surface charge densities of bare, pre-PEG, and post-PEG liposomes were 0.72 µC/ m 2 , 0.26 µC/m 2 , and 0.20µC/m 2 , respectively. We considered that the absolute values of the surface charge density of pre-PEG and post-PEG liposomes were reduced because PEG was present to cover a part of the charge derived from phospholipid on the liposome surface. The values of FALT on the liposomal membrane were calculated from the values of slope derived by linear regression in Fig.  5a . As shown in Fig. 5b , modification of PEG significantly increased the values of FALT. This result indicates that the thickness of the immobilized aqueous layer was increased by the formation of the PEG hydration layer on the liposome surface. It was reported that liposomes with a FALT value of 2.5 nm significantly increased plasma and intratumoral drug concentrations compared to that of 1.0 nm 19 . Therefore, it was suggested that the FALT values of pre-PEG and post-PEG liposomes are sufficient to improve retention in blood. From these findings, we confirmed that bare, pre-PEG, and post-PEG liposomes were prepared successfully.
In vitro release of polyborane from liposomes
The cumulative release of polyborane from liposomes at 37 is shown in Fig. 6 . There was no significant difference, and it was shown that PEGylation methods did not affect the release behavior of polyborane from liposomes. As shown in Fig. 6 , 40 of polyborane was released within 1 h, and the rest showed a slow release. This result suggests that polyborane retained on the liposome surface or lipid membrane caused an initial burst, and polyborane-encapsulated as an ionic form in the aqueous phase of the liposome did not permeate the lipid bilayer membrane 28 .
3.3
In vitro cytotoxicity and cell uptake efficiency of liposomes Figure 7a shows the results of the cytotoxicity tests. The encapsulation of polyborane in liposomes tended to reduce the cytotoxicity, and particularly in RAW 264.7, which is a macrophage-derived mouse cell line, the cytotoxicity of polyborane was significantly reduced in all liposomal suspensions as compared to the polyborane solution. In addition, it was found that PEGylation methods do not affect cell viability. As shown in Fig. 7b , liposomal suspension significantly increased the uptake efficiency of polyborane in B16 melanoma and RWA264.7 cells as compared to polyborane solution. The interaction mechanism between the liposome and the cell is roughly classified into three: adsorption and binding of the liposome to the cell surface, uptake of the liposome into the cell by endocytosis, and fusion of the liposome membrane and the cell membrane 29 . Endocytosis can be classified as phagocytosis and pinocytosis, and the mechanism for incorporating nanosized particles is mainly pinocytosis 30 32 . This result indicates that the liposomes used in this study are more susceptible to cell adhesion and uptake than the simple solution. In addition, compared to bare liposomes, the uptake efficiency in RWA264.7 cells of PEGylated liposomes was reduced. It is suggested that PEG hydration layer formed on the surface of the PE-Gylated liposome inhibited the adsorption of the liposomes to RAW264.7 cells. In B16 melanoma cells, the number of boron atoms per cell of bare, pre-PEG, and post-PEG liposomes were 1.96 10 12 atoms/cell, 1.27 10 12 atoms/cell, and 1.33 10 12 atoms/cell, respectively. From this result, we confirmed that these liposomes can deliver sufficient amount of boron 10 8 -10 9 10 B atoms/tumor cell to B16 melanoma cells for effective BNCT 33 . 
Biodistribution of liposomes
Figures 8 shows boron concentrations of blood, tumor, urine, feces, and all organs brain, heart, lungs, liver, stomach, pancreas, spleen, and kidneys . The average boron concentrations in the tumor of pre-PEG and post-PEG liposomes reached 77.6 µg/g of tissue, and 73.2 µg/g of tissue at 24 h after injections, respectively. Moreover, these liposomes significantly increased the boron concentration in the tumor compared to bare liposomes. From this result and Fig. 7b , we considered that the retention times of these liposomes in circulation were prolonged as the PEG hydration layer formed on the surface of these liposomes inhibited adsorption to serum proteins and macrophages 3 . It is reported that the intratumoral 10 B concentration required to perform sufficient BNCT is 20-30 µg/ g 11 . Naturally occurring boron contains 19.8 10 B and 80.2 11 B 34 . This intratumoral concentration can be achieved by replacing 3-4 of the 10 boron atoms in the polyborane used in this study with 10 B. Tumor/blood ratio of boron concentration, which is the ratio of a boron concentration of tumor divided by that of blood, was also calculated from the results shown in Fig. 8 . In the liposomal suspensions, average tumor/blood ratios reached over 5.5 at 24 h after injection, whereas that of polyborane solution was 4.4. In other organs, the boron concentrations were 30 µg/g of tissue or less, and in the liver, it was less than 4 µg/ g of tissue. The low boron concentration in the liver and high boron concentration in the feces suggest that polyborane hardly accumulated in the liver and rapidly migrated into the bile from the liver. The amount of polyborane excreted in urine in the polyborane solution administered group tended to be higher than in the liposomal suspensions administered group. The nanoparticles with a diameter of 100 nm are not eliminated by the glomerular filtra- tion 35 . Thus, it was assumed that the polyborane released from liposomes in the blood circulation was excreted by renal excretion. From these results, it was confirmed that biodistribution of post-PEG liposomes was similar to pre-PEG liposomes.
Conclusion
We have prepared polyborane-encapsulated PEGylated liposomes that show equivalent efficacy with half the amount of PEG lipid used in the conventional method by using post-insertion technique. The calculated results of surface chase density and FALT showed that there was no difference in PEG modification of the liposome surface in post-PEG liposomes and pre-PEG liposomes. In vitro cell viability, in vitro cell uptake efficiency, and in vivo biodistribution of post-PEG liposomes were similar to that of pre-PEG liposomes. The results of this study will facilitate the use of post-insertion technique in research for BNCT and will contribute to the development of liposome formulations using PEG lipids and ligands.
